Physician profile
Kathryn C Brown
NPI 1447299151
$3,237.06
in general payments reported to CMS, 2019-2025
25 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $170 · 2022: $69.98 · 2023: $959 · 2024: $774 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.57 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $459.78 | 2019-2025 | Hizentra, Haegarda |
| Astrazeneca Pharmaceuticals Lp | $371.93 | 2019-2025 | Bevespi Aerosphere, Fasenra, Tezspire |
| Pharming Healthcare, INC. | $285.26 | 2019-2024 | Ruconest |
| Glaxosmithkline, LLC. | $273.48 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Shire North American Group INC | $236.39 | 2019 | |
| Genentech USA, INC. | $232.19 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $204.49 | 2019-2024 | |
| Genzyme Corporation | $181.21 | 2019-2025 | |
| Blueprint Medicines Corporation | $135.85 | 2023-2024 | Ayvakit |
| Pfizer INC. | $135.28 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $132.05 | 2019-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Alk-Abello, INC | $91.46 | 2019-2024 | Ragwitek, Odactra, Grastek |
| Optinose US, INC. | $74.54 | 2019-2024 | |
| Kaleo, INC. | $63.76 | 2019-2023 | Auvi-Q |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $59.39 | 2023-2024 | Orladeyo |
| Grifols USA, LLC | $39.75 | 2019 | |
| Abbvie INC. | $30.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.33 | 2025 | Hyqvia |
| Mylan Specialty L.P. | $22.46 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2023 | Spiriva Respimat |
| Seqirus USA INC | $18.28 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $17.12 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $13.68 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.